About CRISPR Therapeutics
CRISPR Therapeutics is a company based in Basel (Switzerland) founded in 2013. CRISPR Therapeutics has raised $127 million across 9 funding rounds from investors including Vertex Pharmaceuticals, New Leaf Venture Partners and Franklin Templeton. The company has 393 employees as of December 31, 2024. CRISPR Therapeutics offers products and services including CASGEVY. CRISPR Therapeutics operates in a competitive market with competitors including Alnylam, Editas Medicine, Poseida Therapeutics, Ultragenyx and Senti Biosciences, among others.
- Headquarter Basel, Switzerland
- Employees 393 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Crispr Therapeutics Ag
-
Annual Revenue
$37.31 M (USD)-89.95as on Dec 31, 2024
-
Net Profit
-$366.25 M (USD)-138.43as on Dec 31, 2024
-
EBITDA
-$447.31 M (USD)-120.67as on Dec 31, 2024
-
Total Equity Funding
$127 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Vertex Pharmaceuticals
& 11 more
-
Employee Count
393
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CRISPR Therapeutics
CRISPR Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CRSP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CRISPR Therapeutics
CRISPR Therapeutics offers a comprehensive portfolio of products and services, including CASGEVY.
Treatment for sickle cell disease and beta thalassemia using gene editing.
People of CRISPR Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of CRISPR Therapeutics
CRISPR Therapeutics has successfully raised a total of $127M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CRISPR Therapeutics
CRISPR Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Vertex Pharmaceuticals, New Leaf Venture Partners and Franklin Templeton.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked |
Investor details for CRISPR Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CRISPR Therapeutics
Investment portfolio details for CRISPR Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CRISPR Therapeutics
Detailed financials for CRISPR Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crispr Therapeutics Comparisons
Peer comparison for CRISPR Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CRISPR Therapeutics
CRISPR Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Editas Medicine, Poseida Therapeutics, Ultragenyx and Senti Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
Detailed competitors of CRISPR Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crispr Therapeutics
Complete news archive for CRISPR Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CRISPR Therapeutics
CRISPR Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
CRISPR Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
CRISPR Therapeutics is a funded company, having raised a total of $127M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CRISPR Therapeutics is 393.
Annual revenue of CRISPR Therapeutics is $37.31M as on Dec 31, 2024.
CRISPR Therapeutics was founded in 2013 and is headquartered in Basel, Switzerland. Operations center on the biotechnology sector, where gene-editing tools like CRISPR-Cas9 are applied to create therapies for hemoglobinopathies, cancer, and regenerative medicine. Focus is placed on translating this technology into treatments for serious genetic conditions, with activities spanning research and development in human disease solutions.
CRISPR Therapeutics's top competitors include Alnylam, Senti Biosciences and BioMarin Pharmaceutical.
CRISPR Therapeutics offers CASGEVY.
Yes, CRISPR Therapeutics is publicly traded on NASDAQ under the ticker symbol CRSP.
CRISPR Therapeutics has 12 investors. Key investors include Vertex Pharmaceuticals, New Leaf Venture Partners, Franklin Templeton, Jefferies, and Celgene.
The ticker symbol of CRISPR Therapeutics is CRSP on NASDAQ.